Affordable Access

Access to the full text

Trospium chloride extended release is effective and well tolerated in women with overactive bladder syndrome

Authors
  • Sand, Peter K.1, 2
  • Dmochowski, Roger R.3
  • Zinner, Norman R.4
  • Staskin, David R.5
  • Appell, Rodney A.6
  • 1 University of Chicago, Division of Urogynecology and Reconstructive Surgery, NorthShore University HealthSystem, Pritzker School of Medicine, Evanston, IL, USA , Evanston (United States)
  • 2 Evanston Continence Center, 1000 Central Street, Suite 730, Evanston, IL, 60201, USA , Evanston (United States)
  • 3 Vanderbilt University School of Medicine, Nashville, TN, USA , Nashville (United States)
  • 4 Western Clinical Research, Torrance, CA, USA , Torrance (United States)
  • 5 Tufts University School of Medicine, Division of Urology, Caritas St. Elizabeth’s Medical Center, Boston, MA, USA , Boston (United States)
  • 6 Baylor College of Medicine, Houston, TX, USA , Houston (United States)
Type
Published Article
Journal
International Urogynecology Journal
Publisher
Springer-Verlag
Publication Date
Aug 29, 2009
Volume
20
Issue
12
Pages
1431–1438
Identifiers
DOI: 10.1007/s00192-009-0969-8
Source
Springer Nature
Keywords
License
Yellow

Abstract

Introduction and hypothesisTo confirm the efficacy and tolerability of extended release (ER) trospium chloride in women with overactive bladder syndrome (OAB), data from two identical phase III studies were analyzed.MethodsAdults (aged ≥ 18 years) who had OAB with urinary urgency, frequency, and urge urinary incontinence (UUI) were randomized to trospium ER 60 mg or placebo once daily for 12 weeks. The analysis included 989 women (trospium ER, n = 484; placebo, n = 505). Endpoints examined included changes from baseline in number of toilet voids and UUI episodes/day at week 12. Continuous data were analyzed using rank analysis of variance.ResultsAt week 12, significantly greater mean reductions in numbers of toilet voids and UUI episodes/day occurred with trospium ER versus placebo (P < 0.0001). Adverse events considered at least possibly related to treatment with trospium ER included dry mouth (11.4%) and constipation (8.9%).ConclusionsTrospium ER was effective and well tolerated in women with OAB.

Report this publication

Statistics

Seen <100 times